Clinical Trial Update: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Azenosertib (ZN-c3) in platinum-resistant high-grade serous ovarian cancer and related fallopian tube or primary peritoneal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Serous Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Azenosertib (azenosertib)

Snippet

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | Status: RECRUITING